Demographic and clinical characteristics at baseline for all patients, for those in trials currently providing long-term follow-up (LTFU) data, and in terms of whether or not Vasculitis Damage Index (VDI) data were present at LTFU
| All patients (n=735) | Patients eligible for LTFU (n=535) | Patients with VDI data at LTFU (n=302) | Patients without VDI data at LTFU (n=233) | p Value | |
|---|---|---|---|---|---|
| Diagnosis, n (%) (n=735) | |||||
| Microscopic polyangiitis (MPA) | 332 (45.2) | 254 (47.5) | 135 (44.7) | 119 (51.1) | |
| Granulomatosis with polyangiitis (GPA) | 403 (54.8) | 281 (52.5) | 167 (55.3%) | 114 (48.9) | 0.169* |
| Sex, n (%) (n=735) | |||||
| Male | 415 (56.5) | 288 (53.8) | 154 (51.0) | 134 (57.5) | |
| Female | 320 (43.5) | 247 (46.2) | 148 (49.0) | 99 (42.5) | 0.158* |
| Age, years, mean (SD) (n=735) | 57.6 (14.4) | 57.7 (14.3) | 56.8 (14.6) | 58.9 (13.9) | 0.093† |
| Trial, n (%) (n=735) | |||||
| NORAM | 95 (12.9) | 95 (17.8) | 55 (18.2) | 40 (17.2) | |
| CYCAZAREM | 155 (21.1) | 155 (29.0) | 84 (27.8) | 71 (30.5) | |
| MEPEX | 137 (18.6) | 137 (25.6) | 61 (20.2) | 76 (32.6) | |
| CYCLOPS | 148 (20.1) | 148 (27.7) | 102 (33.8) | 46 (19.7) | 0.001* |
| IMPROVE | 156 (21.2) | 0 | 0 | 0 | |
| RITUXIVAS | 44 (6.0) | 0 | 0 | 0 | |
| Serum creatinine (µmol/L) median (IQR) (n=729) | 192 (98.7 to 440) | 203 (96.8 to 498) | 176 (91.4 to 413.3) | 257 (100 to 613.5) | 0.002‡ |
| Haemoglobin g/dL median (IQR) (n=728) | 9.9 (9.7 to 11.5) | 9.8 (8.6 to 11.5) | 9.9 (8.7 to 11.6) | 9.6 (8.45 to 11.4) | 0.065‡ |
| WBC 109/L median (IQR) (n=728) | 11.0 (8.6 to 14.4) | 10.8 (8.4 to 13.7) | 10.7 (8.3 to 13.6) | 11.1 (8.45 to 14.2) | 0.549‡ |
| Platelets 109/L median (IQR) (n=728) | 366 (281 to 490 | 364 (276 to 482) | 361 (272.5 to 490 | 367 (286.5 to 474) | 0.975‡ |
| CRP mg/L median (IQR) (n=726) | 54 (16 to 120) | 54 (18 to 118) | 51 (16.8 to 112.3) | 63 (18.2 to 133.5) | 0.296‡ |
| ESR mm/h median (IQR) (n=571) | 80 (44 to 102) | 91 (58 to 125) | 85 (46 to 117.8) | 100 (68.5 to 150) | 0.001‡ |
| ANCA ELISA only, n (%) (n=704) | |||||
| MPO | 243 (34.5) | 174 (32.5) | 95 (31.5) | 79 (33.9) | |
| PR3 | 394 (56.0) | 286 (53.5) | 170 (56.3) | 116 (49.8) | |
| Double positive | 16 (2.3) | 16 (3.0) | 6 (2.0) | 10 (4.3) | |
| Negative | 51 (7.2) | 51 (9.5%) | 30 (9.9) | 21 (9.0) | 0.040* |
| ANCA ELISA or IIF, n (%) (n=723) | |||||
| MPO | 277 (38.3) | 205 (38.3) | 110 (36.4) | 95 (40.8) | |
| PR3 | 411 (56.8) | 288 (53.8) | 172 (57.0) | 116 (49.8) | |
| Double positive | 16 (2.2) | 16 (3.0) | 6 (2.0) | 10 (4.3) | |
| Negative | 19 (2.6) | 18 (3.4) | 13 (4.3) | 5 (2.1) | 0.015* |
| BVAS score, median (IQR) (n=685) | 16 (10 to 23) | 17 (12 to 23) | 16.5 (12 to 23) | 17 (11.5 to 23) | 0.967‡ |
| BVAS quartiles, n (%) (n=685) | |||||
| 0–10 | 174 (25.4) | 111 (20.7) | 57 (18.9) | 54 (23.2) | |
| 11–16 | 170 (24.8) | 152 (28.4) | 94 (31.1) | 58 (24.9) | |
| 17–23 | 179 (26.1) | 152 (28.4) | 87 (28.8) | 65 (27.9) | |
| 24+ | 162 (23.7) | 120 (22.4) | 64 (21.2) | 56 (24.0) | 0.323* |
| Total VDI scores, n (%) (n=629) | |||||
| 0 | 412 (65.5) | 350 (71.7) | 223 (74.3) | 127 (67.6) | |
| 1–2 | 133 (21.1) | 88 (18.0) | 50 (16.7) | 38 (20.2) | |
| 3–4 | 52 (8.3) | 32 (6.6) | 19 (6.3) | 13 (6.9) | |
| >=5 | 32 (5.09) | 18 (3.7) | 8 (2.7) | 10 (5.3) | 0.283* |
Data are shown as n (%), mean (SD), or median with IQR.
*Pearson test (χ2).
†t Test.
‡Mann-Whitney U test.
ANCA, antineutrophil cytoplasm antibody; BVAS, Birmingham vasculitis activity score; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count.